Showing results (41-50 of 52) with videos related to
Sort By:
Pageof 6
Journal of Pharmaceutical and Biomedical Analysis|March 12, 2025
An efficient approach to probe bioactive components of herbal patches by 2D-carbon microfiber fractionation and multi-chamber membrane separation electrophoresis: Spatholobus suberectus Dunn as a caseLei Yang, Haiyan Cui, Meiyu Cui, et al.Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences|December 15, 2023
[Significance of anti-Jo-1 antibody's clinical stratification in idiopathic inflammatory myopathy and disease spectrum]Jia Chen Li, Zhan Hong Lai, Miao Shao, et al.Journal of Immunology Research|June 18, 2019
Tissue-Specific Autoantibodies Improve Diagnosis of Primary Sjögren's Syndrome in the Early Stage and Indicate Localized Salivary InjuryYuebo Jin, Jing Li, Jiali Chen, et al.Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences|April 10, 2024
[Low disease activity and remission status of systemic lupus erythematosus in a real-world study]Limin Ren, Chuchu Zhao, Yi Zhao, et al.Frontiers in Oncology|March 22, 2021
Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 PatientsXin-Yu Ren, Yu Song, Jing Wang, et al.Plos Pathogens|October 7, 2021
Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosusPengcheng Zhou, Jiali Chen, Jing He, et al.Signal Transduction and Targeted Therapy|March 7, 2022
Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trialXiaoying Zhang, Miao Miao, Ruijun Zhang, et al.Immunology|September 3, 2022
Dynamics of T follicular helper cells in patients with rheumatic diseases and subsequent antibody responses in a three-dose immunization regimen of CoronaVacXingyu Zhou, Yifan Wang, Bo Huang, et al.Nature Communications|January 7, 2026
Efficacy and safety of low-dose interleukin 2 for Behçet's syndrome: a randomized, placebo-controlled, double-blind, phase 2 clinical trialTian Liu, Wenyan Zhou, Yan Zhu, et al.Annals of the Rheumatic Diseases|September 21, 2019
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trialJing He, Ruijun Zhang, Miao Shao, et al.Pageof 6